Topic
myasthenia-gravis
1 stories related to this topic, newest first.
Substrate placeholder — needs reviewscience83 days ago
Trial Data: Nipocalimab Reduces IgG by 64% in Myasthenia Gravis Patients Over 120 Weeks
Johnson & Johnson's Imaavy (nipocalimab) showed sustained improvements in generalized myasthenia gravis through 120 weeks, according to seekingalpha.com. The treatment cut IgG levels by 64% and boosted symptom control. Imaavy is a product developed by J&J.